Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (489)	7/18/2002 2:43:36 PM
From: Jibacoa	Respond to of 544

DGEN Although it seems to have found support at the $2 level, from where it started a slow up-move on July 11, so far it hasn't showed any reaction to its recent news about its discovery of a drug target, designated DT022I, for the potential treatment of inflammatory diseases, including rheumatoid arthritis. That is the third drug development target announced by DGEN from its inflammatory disease program.<g> siliconinvestor.com It needs to close above 3 before it can think of testing the resistance at the 3.95 to 4.25 The long term average line on the daily chart stands at 3.50 at present. siliconinvestor.com Bernard